key: cord-0684050-6klruo8c authors: Yang, Limin; Tian, Deyu; Han, Jian-bao; Fan, Wenhui; Zhang, Yuan; Li, Yunlong; Sun, Wenqiang; Wei, Yanqiu; Tian, Xiaodong; Yu, Dan-dan; Feng, Xiao-li; Cheng, Gong; Zheng, Yong-tang; Bi, Yuhai; Liu, Wenjun title: A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates date: 2021-03-30 journal: bioRxiv DOI: 10.1101/2021.03.30.437647 sha: 964e81ed1bb32b49d4e5bad4ef4a884968cbb45e doc_id: 684050 cord_uid: 6klruo8c Safe and effective vaccination is critical to combatting the COVID-19 pandemic. Here, we developed a trimeric SARS-CoV-2 receptor-binding domain (RBD) subunit vaccine candidate that simulates the natural structure of the spike (S) trimer glycoprotein. Immunization with RBD-trimer induced robust humoral and cellular immune responses and a high level of neutralizing antibodies that were maintained for at least 4 months. Moreover, the antibodies that were produced in response to the vaccine effectively neutralized the SARS-CoV-2 501Y.V2 variant. Of note, when the titers of the antibodies dropped to a sufficiently low level, only one boost quickly activated the anamnestic immune response, resulting in complete protection against the SARS-CoV-2 challenge in rhesus macaques without typical histopathological changes or viral replication in the lungs and other respiratory tissues. Our results indicated that immunization with SARS-CoV-2 RBD-trimer could raise long-term and broad immunity protection in nonhuman primates, thereby offering an optimal vaccination strategy against COVID-19. 4 antibody-dependent enhancement (ADE), leading to a potential risk of vaccine 66 enhancement of disease [17, 18] . The principle is that the nonneutralizing antibodies 67 produced in response to the vaccine mediate virus infection via the Fcγ receptor [18] . 68 Considering the high degree of homology of SARS-CoV-2, the potential ADE effect 69 needs to be considered seriously in designing COVID-19 vaccines. To mitigate the 70 ADE effect, minimizing nonneutralizing epitopes and keeping only the critical 71 neutralizing epitope to elicit robust protective immunity is a solution [19] . binding domain (RBD) located at the C-terminus of the S1 subunit has thus attracted 73 attention. Several lines of evidence have indicated that RBD-specific antibodies could 74 minimize the ADE effect [20] , and most discovered potent neutralizing antibody (NAb) 75 target the RBD region [21, 22] . SARS-CoV-2 initiates viral replication by binding via the 76 RBD to the cell surface receptor angiotensin-converting enzyme 2 (ACE2). Hence, the 77 RBD can be used as a vaccine target to block viral attachment. Additionally, the RBD 78 possesses T cell epitopes, which can provoke antiviral T cell responses [11, 12] . However, 79 the molecular weight of the RBD is small, which leads to its weak immunogenicity. 80 Some researchers have tried to express it by fusion with the Fc domain and prepare it 81 as a dimer, thereby greatly enhancing its immunogenicity [13] . Some evidence has shown 82 that the NAb level in SARS-CoV-2-infected humans significantly declines from the 83 second month and can even be lost [23] , allowing them to be reinfected [24] . This short-84 lasting antibody protection poses a severe challenge for vaccine development. In 85 addition, SARS-CoV-2 is characterized by a high mutation rate, and some evidence has 86 proven that the 501Y.V2 variant (B.1.351) that emerged in South Africa severely 87 5 reduced the protective efficacy of licensed mRNA vaccines [25] [26] [27] . Therefore, a vaccine 88 strategy that can produce persistent and broad protection is particularly important. 89 In the present study, we designed and developed an RBD trimer as a candidate SARS- Ethical statement 102 The protocols of all animal experiments were approved by Kunming National High- Gene construction and protein generation 123 The RBD region (residues Ser325 -Ser530) of the SARS-CoV-2 S protein (accession No. China). Briefly, NHP PBMCs were added to a plate (1×10 6 /well) and then stimulated 283 with S1 protein (2 μg/ml in each well) or RPMI 1640 medium as a control for 5 h. 396 We next assessed the protective efficacy of the RBD-trimer vaccine against SARS- CoV-2 infection in R. macaques; all the macaques were intranasally and tracheally 398 challenged with 1×10 7 TCID50 of the SARS-CoV-2 20SF107 strain at 9 days after the 399 second booster vaccination ( Fig. 2A) . Throat, nose, and rectal swabs and tracheal brush RBD vaccine candidate could confer sterilizing immunity in lung tissues (Fig. 3E ). Additionally, no clinical signs were found in the immunized macaques after challenge, 413 while the control macaques exhibited symptoms, including cough and increased body 414 temperature (Fig. 3F) . was observed in the lung tissues from immunized macaques (Fig. 4A, B) . In contrast, 419 severe histopathological changes were found in the control macaques, including 420 apparent thickened alveolar walls, mononuclear inflammatory cell infiltration, focal 421 exudation, hemorrhage, and architecture disappearance (Fig. 4C, D) . Immunohistochemical (IHC) assays indicated that multiple pneumocytes in the lung 423 sections from the control macaques were positive for SARS-CoV-2 N protein staining 424 (Fig. 4G, H) . By contrast, no viral antigen was detected in the lung tissues from the 425 immunized animals (Fig. 4E, F) . showed that older macaques developed extreme viral replication in the lungs [29] . Therefore, the protective effect of vaccines for middle-aged and frail people is highly 483 valuable. Thus, our vaccination group included a frail macaque (#140829, 6 years old, To improve the immunogenicity of the recombinant RBD protein and better mimic 503 the native trimeric SARS-CoV-2 S structure, we fused a trimer motif to make the RBD 504 form a stable trimer structure; the construct will not dissociate even if the temperature 505 is above 60℃, and there was no change after 3 months of storage at 4℃. Western blot 506 analysis showed that compared with the monomer, the trimer binds to the SARS-CoV-507 2 S1 polyclonal antibody more strongly, suggesting that the conformational epitope is 508 better retained. be more easily transmitted [30] . There is a growing concern that the N501Y.V2 and 523 N501Y.V3 variants could impair the protective efficacy of licensed vaccines [26] . Therefore, the broad-spectrum protection of the vaccine is also a focus of our attention. 525 Previous research reported that the AddaVax adjuvant, a squalene-based oil-in-water 526 emulsion similar to MF59, could increase the broad protection of the influenza virus 527 vaccine by stimulating a cross-protective humoral response [31] . Compared with 528 aluminum adjuvants, squalene-based adjuvants have been shown to induce humoral and 529 cellular immune responses in a more balanced manner [32] . Therefore, we chose this 530 adjuvant to formulate our candidate vaccine. Excitingly, the antibodies produced in 531 response to our vaccine showed good neutralizing activity against N501Y.V2 variant. There were no abnormalities in the vaccinated animals, which means that our vaccine 567 candidate may protect the animals from liver injury. In short, our candidate vaccine 568 can effectively protect the organs of NHPs from virus attacks. Since the antibody level induced by infection or vaccination cannot last overly long, Conflict of interest 594 The authors declare that they have no conflict of interest. Acknowledgments 596 We thank JFS and JHZ from Beijing Primabio Inc for their assistance with husbandry Epidemiological and clinical characteristics of 99 cases of 610 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study Safety, tolerability, and immunogenicity of a recombinant 613 adenovirus type-5 vectored covid-19 vaccine: A dose-escalation, open-label, non-randomised, 614 first-in-human trial Oxford-astrazeneca covid-19 vaccine efficacy Single-shot ad26 vaccine protects against sars-cov-617 2 in rhesus macaques Development of an inactivated vaccine candidate for sars-cov-2. 619 Development of an inactivated vaccine candidate, bbibp-621 corv, with potent protection against sars-cov-2 Immunogenicity of a DNA vaccine candidate for covid-19. 623 DNA vaccine protection against sars-cov-2 in rhesus 625 macaques Safety and immunogenicity of a mrna rabies vaccine 627 in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical 628 trial Evaluation of the mrna-1273 vaccine against sars-cov-630 2 in nonhuman primates A thermostable mrna vaccine against covid-19 A vaccine targeting the rbd of the s protein of sars-cov-2 634 induces protective immunity A universal design of betacoronavirus vaccines against covid-19, 636 mers, and sars Development of a novel platform of virus-like particle 638 (vlp)-based vaccine against covid-19 by exposing epitopes: An immunoinformatics approach Distinct conformational states of sars-cov-2 spike protein Safety and immunogenicity of s-trimer (scb-2019), a 643 protein subunit vaccine candidate for covid-19 in healthy adults: A phase 1, randomised, double-644 blind, placebo-controlled trial Anti-spike igg causes severe acute lung injury by skewing 646 macrophage responses during acute sars-cov infection Molecular mechanism for antibody-dependent enhancement of 648 coronavirus entry Antibody-dependent enhancement and sars-cov-2 650 vaccines and therapies Elicitation of potent neutralizing antibody responses by 652 designed protein nanoparticle vaccines for sars-cov-2 A human neutralizing antibody targets the receptor-binding site 654 of sars-cov-2 Convergent antibody responses to sars-cov-2 in 656 convalescent individuals Rapid decline of neutralizing antibodies against sars-cov-2 658 among infected healthcare workers Seasonal coronavirus protective immunity is 660 short-lasting Serum neutralizing activity elicited by mrna-1273 vaccine -662 36 preliminary report Multiple sars-cov-2 variants escape 664 neutralization by vaccine-induced humoral immunity Antibody resistance of sars-cov-2 variants b.1.351 and b.1.1.7. 666 Analysis of clinical features and outcomes of 161 patients with 668 severe and critical covid-19: A multicenter descriptive study Age-related rhesus macaque models of covid-19 Genomic sequencing in pandemics Adjuvants and immunization strategies to induce 674 influenza virus hemagglutinin stalk antibodies Identification of an ideal adjuvant for receptor-676 binding domain-based subunit vaccines against middle east respiratory syndrome coronavirus Recovery from the middle east respiratory 679 syndrome is associated with antibody and t-cell responses In vitro neutralization assays of immunized rhesus macaque serum The serum samples after three immunizations were used for testing NAb titers by PRNT 685 assay (A), respectively. The sera samples collected on day 7 post the 2 nd boost were 686 used for testing NAb titers by LVV-PsN assay (B). Serial dilutions of serum were pre-687 351) variant, and the percentage 689 inhibition of cell infection were determined. Nonlinear regression was performed using 690 a log (inhibitor) versus normalized response curve and a variable slope model (R2> 691 0.95 for all curves). The EC50 (PRNT) and NT50 (LVV-PsN) were calculated by using 692 the Reed-Muench method Hematological index changes of rhesus macaques after SARS-CoV-2 Macaques were challenged, and hematological values were obtained before and 1, 3, 5, 698 and 7 days after challenge. The solid lines and the dotted lines represent the upper and Serum biochemical index changes of rhesus macaques after SARS-CoV Macaques were challenged, and body temperature and serum biochemical values were 705 measured before and 1, 3, 5, and 7 days after the challenge. The solid lines and the 706 dotted lines represent the upper and lower limits of the normal reference range